Global Monoclonal Antibody Partnering Terms and Agreements 2010-2016: Latest Deal Trends, Players and Financials

Mar 16, 2016, 10:10 ET from Research and Markets

DUBLIN, March 16, 2016 /PRNewswire/ --

Research and Markets ( has announced the addition of the "Global Monoclonal Antibody Partnering Terms and Agreements 2010-2016: Deal trends, players and financials" report to their offering.

The Global Monoclonal antibody Partnering Terms and Agreements 2010 to 2016: Deal trends, players, financials and forecasts report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report provides details of the latest monoclonal antibody agreements announced in the healthcare sectors, covering:

  • Monoclonal antibodies
  • Murine mAb
  • Chimeric mAb
  • Humanized mAb
  • Human aAb

Global Monoclonal antibody Partnering Terms and Agreements 2010 to 2016 includes:

  • Trends in monoclonal antibodies dealmaking in the biopharma industry since 2010
  • Analysis of monoclonal antibodies deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to over 700 monoclonal antibodies deal records
  • The leading monoclonal antibodies deals by value since 2010
  • Includes chimeric mAb, humanized mAb, human mAb and murine mAb deals and alliances since 2010

In Global Monoclonal antibody Partnering Terms and Agreements 2010 to 2016, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Monoclonal antibodies type

Key Topics Covered:

Chapter 1 - Introduction

Chapter 2 - Trends in monoclonal antibody dealmaking

Chapter 3 - Leading monoclonal antibody deals

Chapter 4 - Most active monoclonal antibody dealmakers

Chapter 5 - Monoclonal antibody contracts dealmaking directory

Chapter 6 - Monoclonal antibody dealmaking by technology type 

Chapter 7 - Partnering resource center

For more information visit

Media Contact:

Laura Wood, Senior Manager 

For E.S.T Office Hours Call 1-917-300-0470

 For U.S./CAN Toll Free Call 1-800-526-8630

 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716


SOURCE Research and Markets